Gemzar Ovarian Cancer Data Not Sufficient For Approval In Recurrent Disease, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While FDA advisory committee accepts that Lilly’s Gemzar plus carboplatin may have had an effect on progression-free survival in ovarian cancer, poor study design and lack of overall survival benefit sink approval recommendation.
You may also be interested in...
FDA Reverses ODAC Opinion, Approves Gemzar For Ovarian Cancer
FDA disagreed with the Oncologic Drugs Advisory Committee’s March determination that progression-free survival is not a valid endpoint for ovarian cancer.
FDA Reverses ODAC Opinion, Approves Gemzar For Ovarian Cancer
FDA disagreed with the Oncologic Drugs Advisory Committee’s March determination that progression-free survival is not a valid endpoint for ovarian cancer.
Gemzar Narrow Progression-Free Survival Benefit To Test Oncology Panel's Efficacy Bar
FDA's Oncologic Drugs Advisory Committee will review Lilly's gemcitabine for treatment of advanced ovarian cancer March 13.